Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 750 of 3499 entries
View as:

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00410605 Org: User:
Start: 11/30/06 End: 06/30/14 Due: 06/30/15

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03201458 Org: User:
Start: 02/08/18 End: 02/19/24 Due: 02/19/25

A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT00001696 Org: User:
Start: 04/30/98 End: 03/31/01 Due: 03/31/02

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

Phase: N/A Priority: Normal
NCT ID: NCT00407485 Org: User:
Start: 11/30/06 End: 04/30/14 Due: 04/30/15

A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)

Phase: N/A Priority: Normal
NCT ID: NCT01240590 Org: User:
Start: 01/26/11 End: 12/31/16 Due: 12/31/17

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00016107 Org: User:
Start: 06/30/01 End: - Due: -

Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00004080 Org: User:
Start: 12/31/99 End: - Due: -

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00025363 Org: User:
Start: 11/30/01 End: - Due: -

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Phase: N/A Priority: Normal
NCT ID: NCT00393029 Org: User:
Start: 10/31/06 End: 11/30/08 Due: 11/30/09

Radiation Therapy and the Natural History of Childhood Cancers

Phase: N/A Priority: Normal
NCT ID: NCT00064883 Org: User:
Start: 07/28/03 End: 05/01/20 Due: 05/01/21

Methods in Education for Breast Cancer Genetics

Phase: N/A Priority: Normal
NCT ID: NCT00001806 Org: User:
Start: 04/06/99 End: 12/06/17 Due: 12/06/18

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04108858 Org: User:
Start: 05/20/21 End: 04/29/22 Due: 04/29/23

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00001832 Org: User:
Start: 08/31/99 End: 05/31/10 Due: 05/31/11

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02203513 Org: User:
Start: 01/20/15 End: 08/27/21 Due: 08/27/22

Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00507767 Org: User:
Start: 07/31/07 End: 02/28/10 Due: 02/28/11

Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00079040 Org: User:
Start: 01/31/06 End: 01/31/09 Due: 01/31/10

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06393751 Org: User:
Start: 10/31/25 End: 02/09/28 Due: 02/09/29

Familial Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00001377 Org: User:
Start: 12/31/93 End: 12/31/00 Due: 12/31/01

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06590558 Org: User:
Start: 08/04/25 End: 05/17/27 Due: 05/17/28

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01802333 Org: User:
Start: 02/12/13 End: 06/15/17 Due: 06/15/18

Genetic and Protein Profiling in Normal and Cancerous Breast Tissue

Phase: N/A Priority: Normal
NCT ID: NCT00083733 Org: User:
Start: 05/27/04 End: 11/17/10 Due: 11/17/11

Survey of the Use of Alternative Medical Therapies in Adult Cancer Patients Enrolled in Phase I Clinical Trials

Phase: N/A Priority: Normal
NCT ID: NCT00001695 Org: User:
Start: 04/30/98 End: 01/31/02 Due: 01/31/03

Raloxifene in Preventing Breast Cancer in Premenopausal Women

Phase: N/A Priority: Normal
NCT ID: NCT00019500 Org: User:
Start: 12/31/98 End: 06/30/05 Due: 06/30/06

Voriconazole to Treat Fungal Infections

Phase: N/A Priority: Normal
NCT ID: NCT00001940 Org: User:
Start: 12/31/99 End: 07/31/01 Due: 07/31/02

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00400829 Org: User:
Start: 11/30/06 End: 01/31/11 Due: 01/31/12